Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

April 8, 2021 8:00 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021. The Company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.


Wednesday, April 14, 2021


3:45 PM ET


Corporate presentation

About Viracta Therapeutics, Inc.Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit

Investor Relations Contact:  

Company Contact:

Joyce Allaire                     

Dan Chevallard                                           

LifeSci Advisors                        

Chief Operating Officer and Chief Financial Officer                               

(212) 915-2569                                                          

(858) 771-4193


Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)


Cision View original content to download multimedia:

SOURCE Viracta

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

PRNewswire, Press Releases

Related Entities

Needham & Company